Cancer Res (2026) 86 (8_Supplement): CT244. Taletrectinib is a next-generation, CNS-active, selective ROS1 TKI approved by the US FDA for the treatment of patients (pts) with locally ...

Cancer Research Communications is an open access journal. What does that mean? Because Cancer Research Communications is an open access journal, all published content is immediately freely accessible ...

Cancer Res (2023) 83 (8_Supplement): CT152. Background: MET gene amplification is associated with poor prognosis in gastric cancer (GC) and gastroesophageal junction adenocarcinomas (GEJ). Savolitinib ...

Background: PLB1004, a novel mono-anilino-pyrimidine small molecule inhibitor of EGFR, potently and irreversibly targets exon 20 insertion mutations with IC50 values ranging from 25.67-316.6 nM. The ...

Cancer Res (2023) 83 (7_Supplement): ND02.

Abstract. Conventional therapies targeted towards the primary tumor cell oftentimes do not affect the metastatic cell and, in fact, may promote metastasis. For these reasons, our research has focused ...

Introduction and Background: Salmonella-IL2 (Saltikva) is an attenuated strain of orally administered Salmonella that carries the human gene for IL-2 that colonizes the tumor microenvironment and ...

You do not currently have access to this content.

Abstract. Datopotamab deruxtecan (Dato-DXd) is an antibody-drug conjugate (ADC) consisting of a humanized anti-TROP2 monoclonal antibody linked to a potent DNA topoisomerase I (TOP1) inhibitor payload ...

Abstract. ADAM9 (A Disintegrin And Metalloproteinase 9) is a transmembrane metalloproteinase overexpressed in a wide range of solid tumors, where it promotes tumor progression, metastasis, and poor ...

Cancer Res (2024) 84 (7_Supplement): LB123.

Mol Cancer Ther (2023) 22 (12_Supplement): PR010. Methods: Patients with previously treated, advanced KRAS G12X mutant solid tumors were enrolled at escalating doses of single agent RMC-6236 ...